NexMed Seeks Development Partner For Alprox-TD Topical ED Therapy
This article was originally published in The Pink Sheet Daily
Schering AG terminated a marketing agreement for alprostadil, which is currently facing an open-label Phase III study.
You may also be interested in...
Bayer has met the quota for percentage of shares needed to acquire Schering AG, the firm said June 19
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.